Planned COVID-19 vaccine trials show level of research ahead

14 October 2020

It seems hard to believe that it has only been around eight months since many companies started working on COVID-19 vaccines, with some having already entered late-stage research and the clamor for an approval growing ever louder.

In fact, approved vaccines are already being used by parts of the population in Russia and China, though the western world is still searching for that crucial Phase III evidence that a safe and effective option is ready to be rolled out.

This may come from a vaccine already in Phase III trials, such as the Pfizer (NYSE: PFE) and BioNTech (Nasdaq: BNTX) candidate or the prospect from The University of Oxford and AstraZeneca (LSE: AZN), but this is not guaranteed as those studies may not deliver the desired data.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK